Evidence map›Paper›PMID 28534292›Full record

ArticleThe AAPS journal2017

Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples.

Sven Loebrich, Mingfang Shen, Erika Cohen, Gillian Payne, Ying Chen, Megan Bogalhas, Yiwei Zhao

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sven LoebrichBioAnalytical Sciences, ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts, 02453, USA. sven.loebrich@immunogen.com.
Mingfang ShenBioAnalytical Sciences, ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts, 02453, USA.
Erika CohenBioAnalytical Sciences, ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts, 02453, USA.
Gillian PayneBioAnalytical Sciences, ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts, 02453, USA.
Ying ChenAntibody Production and Purification, ImmunoGen, 830 Winter Street, Waltham, Massachusetts, 02453, USA.
Megan BogalhasAnalytical and Pharmaceutical Sciences, ImmunoGen, 830 Winter Street, Waltham, Massachusetts, 02453, USA.
Yiwei ZhaoBioAnalytical Sciences, ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts, 02453, USA.
ImmunoGen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug-conjugates (ADCs) are an emerging class of biological therapeutics. Mirvetuximab soravtansine is a novel folate receptor alpha (FRα)-targeting ADC which represents a potential new treatment for patients with ovarian and other FRα-positive cancers. Since patient immune responses to biological therapeutics may negatively affect drug efficacy and patient safety, regulatory authorities require rigorous monitoring of patient samples. Taking advantage of the immune system's ability to generate highly specific antibodies, the field has turned to anti-idiotype antibodies as powerful tools for the development of sensitive and specific bioassays. Here, we report the generation and characterization of a highly specific neutralizing anti-idiotype antibody directed against M9346A, the antibody moiety of mirvetuximab soravtansine. The anti-idiotype antibody recognizes M9346A with double-digit picomolar affinity, competes with folate receptor antigen for binding to M9346A, and can be used to develop both anti-drug-antibody and neutralizing antibody assays.

Indexed as

AnimalsAntibodies, Anti-IdiotypicAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingHumansImmunoconjugatesMaytansineMiceAntibodies, Anti-IdiotypicAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingImmunoconjugatesMaytansinemirvetuximab soravtansineAntibody-drug-conjugateAntidrug-antibodyAnti-idiotypeImmunogenicityNeutralizing antibody

Identifiers

PMID28534292
OpenAlexW2619867514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.